Pharmaceutical logistics is also affected by coronavirus and the consequences of the war in Ukraine. In addition to the known challenges, there are the new legal regulations from the BMG: Lauterbach's SHI Financial Stabilization Act, which freezes prices and further weakens Germany as a pharmaceutical location - and this against the backdrop of already declining R&D expenditure and massive supply bottlenecks in connection with dependence on foreign production. Against a backdrop of falling R&D expenditure and massive supply bottlenecks in connection with dependence on foreign production.
Dr. Kai Joachimsen, Managing Director of the BPI, comments on the BMG's planned regulations as follows:
"The prices for basic substances and materials have risen exorbitantly since the outbreak of war - and now the Federal Ministry of Health is further cutting off the pharmaceutical manufacturers by fixing prices at 2009 levels for another four years and increasing the compulsory discounts!"
